Hallux: Funding, Investors & Team (Sep 2026)
Hallux is a privately held clinical-stage pharmaceutical company that develops a new topical dosage form and route of administration for treating onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest that the subungual treatment procedure is safe and well-tolerated. The company’s technology delivers high concentrations of the gold standard antifungal terbinafine directly and selectively to the site of infection without introducing it systemically, where it can affect the liver and interact with other drugs that patients may be taking. It was founded in 2012 and is headquartered in Laguna Hills, California.
Hallux has raised $9.4M across 1 funding round on record, the most recent an undisclosed round of $9.4M announced in Apr 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Hallux Company Profile and Key Stats
Latest funding round on record: Apr 2022.
Hallux Funding Rounds
Hallux Founders and Leadership Team
No contact details are on record for this team yet.
Hallux Funding Compared to Other Biotechnology Startups
Hallux's latest round of $9.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Hallux in Biotechnology and Laguna Hills
Companies Similar to Hallux
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Hallux Funding FAQs
What does Hallux do?
Hallux is a privately held clinical-stage pharmaceutical company that develops a new topical dosage form and route of administration for treating onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest that the subungual treatment procedure is safe and well-tolerated. The company’s technology delivers high concentrations of the gold standard antifungal terbinafine directly and selectively to the site of infection without introducing it systemically, where it can affect the liver and interact with other drugs that patients may be taking. It was founded in 2012 and is headquartered in Laguna Hills, California.
How much funding has Hallux raised?
Hallux has raised $9.4M across 1 round on record. The most recent is an undisclosed round of $9.4M announced in Apr 2022.
When did Hallux last raise funding?
Hallux's most recent funding round on record is an undisclosed round of $9.4M, announced in Apr 2022.
Who is the CEO of Hallux?
Milan Panic is listed as CEO at Hallux.
Where is Hallux headquartered?
Hallux is based in Laguna Hills, California, United States.
How many employees does Hallux have?
Hallux is in the 11-50 employee band.
How does Hallux's funding compare to other Biotechnology startups?
Hallux's latest round of $9.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Hallux Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Hallux is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.